DE602005025110D1 - Heterocyclische verbindungen und deren verwendung als aldosteronsynthaseinhibitoren - Google Patents

Heterocyclische verbindungen und deren verwendung als aldosteronsynthaseinhibitoren

Info

Publication number
DE602005025110D1
DE602005025110D1 DE602005025110T DE602005025110T DE602005025110D1 DE 602005025110 D1 DE602005025110 D1 DE 602005025110D1 DE 602005025110 T DE602005025110 T DE 602005025110T DE 602005025110 T DE602005025110 T DE 602005025110T DE 602005025110 D1 DE602005025110 D1 DE 602005025110D1
Authority
DE
Germany
Prior art keywords
heterocyclic compounds
synthesis inhibitors
aldosterone synthesis
aldosterone
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE602005025110T
Other languages
English (en)
Inventor
Peter Herold
Robert Mah
Vincenzo Tschinke
Christoph Schumacher
Dirk Behnke
Michael Quirmbach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of DE602005025110D1 publication Critical patent/DE602005025110D1/de
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE602005025110T 2004-05-28 2005-05-27 Heterocyclische verbindungen und deren verwendung als aldosteronsynthaseinhibitoren Expired - Fee Related DE602005025110D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH9162004 2004-05-28
CH11572004 2004-07-09
PCT/EP2005/052418 WO2005118541A2 (en) 2004-05-28 2005-05-27 Heterocyclic compounds and their use as aldosterone synthase inhibitors

Publications (1)

Publication Number Publication Date
DE602005025110D1 true DE602005025110D1 (de) 2011-01-13

Family

ID=34993240

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005025110T Expired - Fee Related DE602005025110D1 (de) 2004-05-28 2005-05-27 Heterocyclische verbindungen und deren verwendung als aldosteronsynthaseinhibitoren

Country Status (11)

Country Link
US (1) US20080076794A1 (de)
EP (1) EP1748986B1 (de)
JP (1) JP2008500999A (de)
AR (1) AR050251A1 (de)
AT (1) ATE490241T1 (de)
BR (1) BRPI0510412A (de)
CA (1) CA2568164A1 (de)
DE (1) DE602005025110D1 (de)
IL (1) IL179409A0 (de)
TW (1) TW200608978A (de)
WO (1) WO2005118541A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1765777A2 (de) * 2004-05-28 2007-03-28 Speedel Experimenta AG Bicyclische stickstoffhaltige heterocyclen als aromataseinhibitoren
TW200716105A (en) * 2005-05-31 2007-05-01 Speedel Experimenta Ag Imidazole compounds
TW200804378A (en) * 2005-12-09 2008-01-16 Speedel Experimenta Ag Organic compounds
EP1842543A1 (de) 2006-04-05 2007-10-10 Speedel Pharma AG Pharmazeutishe Zusammensetzung enthaltend einen Aldosteron-Synthase-Inhibitor und einen Mineralkorticoidrezeptor-Antagonist
TW200808813A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200808812A (en) * 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
EP1886695A1 (de) * 2006-06-27 2008-02-13 Speedel Experimenta AG Pharmazeutische Kombinationen mit einem Aldosteron Synthasehemmer und Glucocorticoid Rezeptorantagonisten oder Cortisol Synthasehemmer oder Corticotropin Releasing Faktor Antagonisten
EA201101672A1 (ru) 2009-05-28 2012-06-29 Новартис Аг Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина
AU2010251967B9 (en) 2009-05-28 2014-04-03 Novartis Ag Substituted aminopropionic derivatives as neprilysin inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
CA2841117A1 (en) 2011-07-08 2013-01-17 Novartis Ag 1,2-disubstituted-4-benzylamino-piperidinyl derivatives as cetp inhibitors useful for the treatment of atherosclerosis in high triglyceride subjects
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
PE20151666A1 (es) 2013-02-14 2015-11-19 Novartis Ag Derivados sustituidos del acido bisfenil butanoico fosfonico como inhibidores de la nep
CN105612172A (zh) 2013-07-25 2016-05-25 诺华股份有限公司 用于治疗心力衰竭的环状多肽
PE20160991A1 (es) 2013-07-25 2016-10-15 Novartis Ag Bioconjugados de polipeptidos de apelina sintetica
BR112017014194A2 (pt) 2015-01-23 2018-01-09 Novartis Ag conjugados de ácido graxo de apelina sintéticos com meia-vida melhorada
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
EP3887363A1 (de) 2018-11-27 2021-10-06 Novartis AG Zyklische pentamer-verbindungen als proprotein-konvertase-subtilisin-kexin-typ 9 (pcsk9)-inhibitoren zur behandlung von stoffwechselstörung
CN113166204A (zh) 2018-11-27 2021-07-23 诺华股份有限公司 作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型（PCSK9）抑制剂的环状肽
UY38485A (es) 2018-11-27 2020-06-30 Novartis Ag Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
WO2023084449A1 (en) 2021-11-12 2023-05-19 Novartis Ag Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859691A (en) * 1987-07-08 1989-08-22 Ciba-Geigy Corporation Certain 1,2-benzisoxazole derivatives
GB8820730D0 (en) * 1988-09-02 1988-10-05 Erba Carlo Spa Substituted 5 6 7 8-tetrahydroimidazo/1.5-a/pyridines & process for their preparation
US5057521A (en) * 1988-10-26 1991-10-15 Ciba-Geigy Corporation Use of bicyclic imidazole compounds for the treatment of hyperaldosteronism
EP0401707B1 (de) * 1989-06-05 1994-09-21 Daiichi Pharmaceutical Co., Ltd. Heterocyclische Triazin- oder Triazolo-Verbindungen mit Serotonin 2-Rezeptor-Antagonisten-Wirkung
JP3170273B2 (ja) * 1989-06-05 2001-05-28 第一製薬株式会社 縮合トリアジン誘導体及びその中間体
CA2026792A1 (en) * 1989-11-01 1991-05-02 Michael N. Greco (6,7-dihydro-5h-pyrrolo[1,2-c]imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1h-benzotriazole derivatives
KR100263412B1 (ko) * 1992-01-27 2000-08-01 디르크 반테 아로마타제 억제제로서 피롤로이미다졸릴 및 이미다조피리디닐 치환된 1h-벤즈이미다졸 유도체
JPH0971586A (ja) * 1995-09-07 1997-03-18 Yamanouchi Pharmaceut Co Ltd 新規な二環性縮合イミダゾール誘導体
WO2002102250A1 (en) * 1999-10-22 2002-12-27 Glaxo Group Limited $g(in vivo) imaging
US20030083342A1 (en) * 2002-08-27 2003-05-01 Steele Ronald Edward Combination of organic compounds

Also Published As

Publication number Publication date
AR050251A1 (es) 2006-10-11
CA2568164A1 (en) 2005-12-15
EP1748986B1 (de) 2010-12-01
ATE490241T1 (de) 2010-12-15
IL179409A0 (en) 2007-05-15
WO2005118541A2 (en) 2005-12-15
JP2008500999A (ja) 2008-01-17
BRPI0510412A (pt) 2007-10-23
EP1748986A2 (de) 2007-02-07
TW200608978A (en) 2006-03-16
US20080076794A1 (en) 2008-03-27
WO2005118541A3 (en) 2006-02-02

Similar Documents

Publication Publication Date Title
DE602005025110D1 (de) Heterocyclische verbindungen und deren verwendung als aldosteronsynthaseinhibitoren
DE602005015699D1 (de) Prolinderivate und deren verwendung als dipeptidylpeptidase-iv-inhibitoren
DE602005022115D1 (de) Heteroaromatische chinolinverbindungen und deren verwendung als pde10-inhibitoren
ATE473229T1 (de) Tricyclische verbindungen und deren verwendung als mglur1-antagonisten
ATE472546T1 (de) 5-heteroarylthiazole und deren verwendung als pi3k-inhibitoren
DE602005023639D1 (de) Chinuclidinderivate und deren verwendung als muscarin-m3-rezeptor-antagonisten
ATE501159T1 (de) 1-(d-glykopyranosyl)-3-(4- cyclopropylphenylmethyl)-4-halogenindolderivate und deren verwendung als sglt-inhibitoren
DE602005016890D1 (de) Chinolinderivate und ihre verwendung als mycobakterielle inhibitoren
ATE492545T1 (de) Verbindungen und zusammensetzungen als proteinkinase-hemmer
DE602005010961D1 (de) Phenylcarbazole basierte Verbindungen und deren Verwendung als organische Elektroluminiszierende Vorrichtung
ATE471939T1 (de) Heterocyclische spiro-verbindungen als aldosteronsynthaseinhibitoren
ATE405553T1 (de) Heterocyclische verbindungen als inhibitoren von faktor viia
ATE544758T1 (de) Carboxamidverbindungen und ihre verwendung als calpain-hemmer
ATE473214T1 (de) 2-(4-oxo-4h-chinazolin-3-yl)acetamide und ihre verwendung als vasopressin-v3-antagonisten
DE602005022169D1 (de) Polymerisierbare verbindungen und verwendung davon
ATE498625T1 (de) Heterocyclische spiro-verbindungen als aldosteronsynthaseinhibitoren
IL179405A0 (en) Heterocyclic compounds and their use as aldosterone synthase inhibitors
DE602004021037D1 (de) Phosphororganische indazolderivate und deren verwendung als proteinkinaseinhibitoren
ATE512953T1 (de) Heterocyclische verbindungen
ATE461926T1 (de) Substituierte n-arylsulfonylheterocyclische amine als gamma-sekretase-hemmer
ATE511507T1 (de) Piperidinylcarbonylpyrrolidine und deren verwendung als melanocortinagonisten
ATE517098T1 (de) Acylaminothiazolderivate und deren verwendung als beta-amyloid-inhibitoren
ATE442366T1 (de) Oxazolidinonderivate und ihre verwendung als antibiotika
ATE478059T1 (de) Cinnamoylpiperazinderivate und ihre verwendung als par-1-antagonisten
ATE472524T1 (de) Diaminoalkohole und deren verwendung als renininhibitoren

Legal Events

Date Code Title Description
R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee

Ref document number: 1748986

Country of ref document: EP

R097 No opposition filed against granted patent, or epo opposition proceedings concluded without decision

Ref document number: 1748986

Country of ref document: EP

Effective date: 20110902

R082 Change of representative

Ref document number: 1748986

Country of ref document: EP

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN, DE